ProfileGDS5678 / 1425954_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 66% 66% 66% 65% 66% 65% 66% 65% 63% 66% 67% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.063367
GSM967853U87-EV human glioblastoma xenograft - Control 23.9912266
GSM967854U87-EV human glioblastoma xenograft - Control 33.9829966
GSM967855U87-EV human glioblastoma xenograft - Control 43.9671766
GSM967856U87-EV human glioblastoma xenograft - Control 53.9025265
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0233266
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9830265
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9740666
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9126465
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7367563
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9783266
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0739167
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9956866
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9806466